Icon Back Back to Search Results

Castrate Resistant Prostate Cancer Enhertu Therapy

  • Recruiting
  • Treatment
  • Interventional
  • Drug
  • PHASE2
  • Washington D.C. Veterans Affairs Medical Center
  • 18 Years -

Study Purpose

Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.

Intervention

Drug : Enhertu

Eligibility Requirements

info icon Pathologically confirmed adenocarcinoma of the prostate

info icon Diagnosis of mCRPC

info icon Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen

info icon Ongoing ADT to maintain serum testosterone levels below 50 ng/dL

info icon Formalin fixed paraffin embedded tumor tissue for HER2 immunohistochemistry

info icon Minimum age: 18

info icon History of interstitial lung disease or pneumonitis requiring steroids

info icon Significant coronary vascular disease

info icon Previous exposure to HER2 targeted therapy

Recruiting status

Recruiting

Estimated enrollment

60

 
Study start date

Mar 05, 2025

Study end date

Oct 31, 2028

Last updated

Mar 23, 2025

Primary purpose

Treatment

Design

Interventional

Intervention

Drug

Study phase

PHASE2

Allocation

Na

 

Sponsor:

Washington D.C. Veterans Affairs Medical Center

Collaborator:

Daiichi Sankyo

Cancer Research And Biostatistics

Institute for Clinical Research

Investigator:

Maneesh Jain, MD

Eric Knoche, MD

Linda Verkruyse, MD

Rhonda Bitting, MD

Julie Graff, MD

Bruce Montgomery, MD

David Kosoff, MD

Fayez Estephan, MD

N/A

NCT06610825

Clinic Location Investigator Distance RECRUITING STATUS Contact